Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (QSI) has announced that its Board's Compensation Committee has granted 46,666 restricted stock units (RSUs) to new employees under the company's 2023 Inducement Equity Incentive Plan. The RSUs were granted as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes 25% vesting on December 20, 2025, followed by the remaining amount vesting in 12 equal quarterly installments, contingent on continued employment.
Quantum-Si (Nasdaq: QSI) has announced a significant expansion of its international distribution network, now totaling 15 partners. The expansion covers multiple regions including Western and Eastern Europe, Asia, Middle East, Africa, South America, and the South Pacific. This strategic move, combined with the recently announced Avantor distribution agreement for North America, aims to accelerate the global adoption of their Platinum® product and drive revenue growth from 2025 onwards. The company is focusing on broadening access to research customers globally through these partnerships.
Canada Nickel reported positive assay results from drill hole BAN24-20 at its Bannockburn property, located 65 kilometers south of Timmins. The hole intersected 1.11% nickel over 10.1 metres, including 1.32% nickel, 0.17% copper, and 0.55 g/t palladium + platinum over 4.4 metres.
This mineralized interval is situated 138 metres northwest of BAN24-18, which previously intersected 1.61% nickel over 12.0 metres. The company has completed a new BHEM survey in BAN24-20 to test the continuation of high-grade horizons, revealing two separate lenses of mineralization. Follow-up drilling is currently in progress with hole BAN24-21.
Quantum-Si (Nasdaq: QSI) has launched the Platinum Library Prep Kit, V2, an advanced tool for single-molecule protein sequencing. The new kit offers significant improvements in accessibility and efficiency, reducing hands-on preparation time to under two hours while maintaining precision. Key features include:
- 85% success rate in generating libraries and sequencing results
- Requires fivefold less protein input than V1
- Compatible with standard lab equipment
- Optimized for various protein conditions
The innovation aims to make Next-Gen Protein Sequencing™ more accessible to research labs using QSI's benchtop instrument.
Quantum-Si (Nasdaq: QSI) has launched its new protein Barcoding Kit, designed to revolutionize protein research through multiplexed screening. The kit employs peptide barcodes for efficient protein analysis, particularly beneficial for biopharma research applications including lipid nanoparticle optimization and mRNA therapeutics evaluation. Key features include overnight workflow with minimal hands-on time, ability to detect low-abundance proteins, and relative quantitation across a broad dynamic range. The solution aims to reduce time and costs while maintaining high sensitivity for therapeutic development.
Quantum-Si (QSI) announced major technical advances at its Investor & Analyst event, introducing two key platforms: Platinum Pro and Proteus. Platinum Pro, launching in H1 2025, will offer streamlined workflow, reduced processing time, and custom application development. Proteus, launching in H2 2026, represents a new proteomics platform featuring ultrasensitive detection, automated liquid handling, and rapid sequencing chemistry with 90-minute run times.
The company announced strategic partnerships with Avantor for distribution in US/Canada, NVIDIA for enhanced data processing, SkyWater for consumable platform development, and Planet Innovation for manufacturing support.
Quantum-Si (Nasdaq: QSI) has entered into a distribution agreement with Avantor (NYSE: AVTR) for its Next-Generation Protein Sequencing (NGPS) technology portfolio in the U.S. and Canadian markets. The collaboration will enable broader access to QSI's proteomics solutions across various laboratory settings. The platform utilizes single-molecule sequencing technology for protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis, supporting applications in drug discovery, diagnostics, and clinical research.
Quantum-Si (Nasdaq: QSI) announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance its core technologies using NVIDIA AI and accelerated computing. The partnership aims to enhance data processing speeds to handle increased data volume from Proteus. By combining NVIDIA's computing capabilities with Quantum-Si's single-molecule protein sequencing technologies, they plan to develop a robust data processing system for generating protein insights to advance research, drug discovery, and healthcare AI. The company is already utilizing NVIDIA BioNeMo for protein structure prediction tools.
Quantum-Si (QSI) and SkyWater Technology are expanding their collaboration to develop the consumable for Proteus™, QSI's next-generation protein sequencing platform. This builds upon their existing partnership since 2021 on the first-generation Platinum® platform. SkyWater will continue supplying consumables for Platinum Pro while supporting Proteus commercialization. The new platform aims to enable simultaneous large factor protein sequencing with enhanced accuracy. SkyWater, certified to ISO 13485 Quality Standard for Medical Devices, will leverage its Technology as a Service (TaaS) model and manufacturing capabilities to support this development.
Quantum-Si (Nasdaq: QSI) has announced a partnership with Planet Innovation for the development and manufacturing of its novel proteomics platform, Proteus™. Planet Innovation, which currently manufactures QSI's Platinum® Pro instrument, will expand its role to support Proteus instrument development and serve as the contract manufacturing partner. The partnership aims to bring the platform to market in under two years, with Planet Innovation leveraging its team of over 400 experts in scientific instrumentation and medical devices development. The Platinum® Pro instrument is scheduled to debut in the first half of 2025.